European Commission’s New Regulation Amending IVDR Transitional Provisions: What You Need to Know

Published on:
March 16, 2022
Written by:
Hasma Boudaoui, Mercè Guerra, Ainoa Forteza

The In Vitro Diagnostics Regulation (EU) 2017/746 (IVDR) is the new regulatory framework for In Vitro Diagnostics (IVD), replacing the IVD Directive 98/79/EC (IVDD). Until May 26, 2022, when the IVDR becomes fully applicable, both legal texts coexist. 

 Under the IVDR, the IVD sector is subject to new and stricter regulatory requirements, including a change in the way IVDs are classified. Under the new classification rules, most IVDs currently on the market will change from class A to a higher class (B, C, or D). Under the IVDD, around 90% of IVDs could be self-certified, whereas, under the new IVDR, 80% of IVDs will now require involvement and assessment from Notified Bodies (NBs).  

 Therefore, most IVD manufacturers will need to approach and apply to an NB to be able to commercialize their products in the EU market. This can become a challenging task for several reasons: 

 Since the IVDR was published in 2017, only six NBs have been certified under the IVDR—that’s only one-third of the NBs that were operating under the IVDD 

  • With fewer NBs available and significantly more products needing the involvement of an NB to certify them, NBs are working on their full capacities and the majority are not able to accept requests and emit new certificates under the IVDR1 
  • Consequently, a very low number of certificates have been issued so far by NBs under the IVDR, compared to the certificates which were issued under the IVDD.  

 This contributed to the EC’s proposal to delay the transitional provisions for some specific products. Without this delay, the market could have faced significant disruption in the supply of IVDs in the market for health institutions and the public.

The new proposed transition periods are: 

  • Class A, self-certified: May 26, 2022  
  • Class D: May 26, 2025 
  • Class C: May 26, 2026  
  • Class B: May 26, 2027 
  • Class A, sterile: May 26, 2027  

Arrow on the classes

Although manufacturers now have the new transition periods as time buffers, it is important to emphasize that May 26, 2022, is still the IVDR Date of Application and that manufacturers will need to comply with some IVDR requirements starting from that day.  Therefore, manufacturers should still aim to apply the IVDR requirements as soon as possible in order to be able to put the products on the market at due time and avoid certification bottleneck. An effective transition strategy and immediate implementation of the requirements will allow a company to be better prepared for the NB assessment and minimize expenses related to the IVDR transition. 

About Alira Health

Alira Health’s Regulatory Affairs team can support manufacturers with a smooth transition from IVDD to IVDR by:

  • Assessing the IVD classification under the new IVDR rules
  • Analyzing the already-generated IVDD data to see if it will comply with the IVDR requirements (gap analysis)
  • Building a regulatory strategy and roadmap for IVDR regulatory compliance of the device
  • Implementing the IVDR requirements and building the technical documentation of the device for submission to authorities
  • Helping with other regulatory activities, including risk management, setting up a post
    market surveillance system, and implement a quality management system


  • CE: Conformité Européenne
  • EC: European Commission
  • IVDR: In Vitro Diagnostics Regulation
  • IVD: In Vitro Diagnostics
  • IVDD: In Vitro Diagnostics Directive
  • NB: Notified Bodies

Related news

Events September 28, 2023
Regulatory Roundup
Look for our clinical development experts Chris Rao and Kenny Carberry as delegates onsite at MassMedic Regulatory Roundup.
MedTech Regulatory
Publications September 22, 2023
Impact of the New EU HTA Regulation on Access to Innovative Medicines in Europe
In this interview, Alira Health Partner Chus Castillo gives updates on HTA Regulation, related challenges, and potential effect on access to innovative medicines.
Biotech Healthcare Technology Regulatory Spain
Publications August 1, 2023
The EU Pharmaceutical Package: Impact on Orphan Medicinal Products
This article reviews the proposed changes in the EU Pharma Package for data protection related to orphan medicinal products (OMPs).
EU Pharma Regulatory
Publications July 10, 2023
The EU Pharmaceutical Package: Regulatory Protection Changes
Our regulatory experts present a more detailed analysis of the proposed changes introduced to Regulatory Data Protection (RDP).
EU Pharma Regulatory
Publications June 14, 2023
Medical Device Regulation: A Checklist for Preparation
This checklist can provide you with insight into where you stand in regards to MDR preparation and what you still need to address.
Medical Devices Regulatory
Publications May 25, 2023
The EU Pharmaceutical Package: Introduction to Changes
Alira Health’s Regulatory experts explore how the proposed package will disrupt the European regulatory landscape and what it means for companies.
EU Pharma Regulatory
News February 21, 2023
Access and reimbursement pathways for digital health solutions and IVD devices
Digital therapeutics (DTx) are innovative solutions that use meaningful data to provide evidence-based decisions for the prevention, treatment, and management of diseases. Particular(...)
Diagnostics Digital Therapeutics Market Access Regulatory Research and Development
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.